Advanced Decision Analysis: Markov Models

Similar documents
Cost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M

Health technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS).

Selection of aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients: a Markov model

Quantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines. Patrick Ryan 21 April 2010

Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V

A cost-utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients Stylopoulos N, Gazelle G S, Rattner D W

Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A, Speier W, Hanlon A, Beck J R, Pollack A

How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E

Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H

Shared Decision Making screening for abdominal aortic aneurysm. Deciding whether to get screened for an abdominal aortic aneurysm (AAA)

Deciding whether to get screened for an abdominal aortic aneurysm (AAA)

Use of discrete event simulation in health service planning: a luxury or necessity? Ruth Davies

Surgery for patients with diffuse atherosclerotic disease

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

BOWLING-PFIZER HEART VALVE SETTLEMENT 2007 AMENDED VALVE REPLACEMENT GUIDELINES

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Making comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Quality Measures MIPS CV Specific

Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B

Technical Meeting on: Current Role of Nuclear Cardiology in the Management of Cardiac Diseases Vienna, May 2008 Vienna International Centre

Supplementary Online Content

Decision Analysis. John M. Inadomi. Decision trees. Background. Key points Decision analysis is used to compare competing

Real-world observational data in costeffectiveness analyses: Herceptin as a case study

Fractional Flow Reserve: Review of the latest data

The Ross Procedure: Outcomes at 20 Years

initial DUS imaging followed by contrast-enhanced magnetic resonance angiography (CEMRA) when DUS demonstrates 50% or higher stenosis;

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

Cost-effectiveness of surgery for small abdominal aortic aneurysms on the basis of data from the United Kingdom small aneurysm trial

Appendix E Health Economic modelling

Project 1: Circulation

A CASE STUDY OF VALUE OF INFORMATION

Cost-effectiveness of preventing hip fracture in the general female population Kanis J A, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B

Abdominal Aortic Aneurysm (AAA) Screening

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A

Treating very short necks ( 4mm <10mm) using the Endurant stent graft + EndoAnchors: 1-year results and current insights

Prognosis. VCU School of Medicine M1 Population Medicine Class

Prevention: When Do Benefits Start and End? What Do They Have in Common?

Appendix E Health Economic modelling

Can Universal Screening for rare conditions ever be cost-effective? The case of Newborn Screening for Biliary Atresia

A FAMILY HISTORY OF ABDOMINAL AORTIC ANEURYSM (AAA) DISEASE

Figure 1 The Human Heart

The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting

Setting The setting was the community. The economic study was carried out in the USA.

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

INRODUCTION TO TREEAGE PRO

New Imaging for Aortic Valve Disease. Anthony DeMaria Judy and Jack White Chair Director, Sulpizio CV Center University of California, San Diego

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer Bayoumi A M, Brown A D, Garber A M

C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders

Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel

Summary 1. Comparative effectiveness of ataluren Study 007

1. Comparative effectiveness of liraglutide

Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U

Setting The setting was primary care. The economic study was carried out in the UK.

FFR Incorporating & Expanding it s use in Clinical Practice

CVD risk assessment using risk scores in primary and secondary prevention

The cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y

Setting The setting was primary care. The economic study was carried out in the USA.

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Supplementary Online Content

Cost-Effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease

Abdominal Aortic Aneurysm (AAA)Screening. Elizabeth Rennie

CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD. Teo et al, Canadian Journal of Cardiology 2014;30:

Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer Konski A

S. Bruce Greenberg, MD FNASCI and President, NASCI Professor of Radiology and Pediatrics University of Arkansas for Medical Sciences

CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough

Indications and Outcomes of the Double Switch in cctga. David Barron Birmingham, UK

A Markov model of secondary prevention of osteoportic hip fractures.


42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim

Cost-Effectiveness of Fractional Flow Reserve

Type of intervention Secondary prevention and treatment; Other (medication coverage policy design).

Source of effectiveness data The effectiveness evidence came from a review of published studies and the authors' assumptions.

Update: Chronic Lymphocytic Leukemia

Understanding Risk Factors for Stroke

*(a) Describe the blood clotting process. (4)

Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme

Northern Ireland Abdominal Aortic Aneurysm (AAA) Screening Programme

Update interventional Cardiology Hans Rickli St.Gallen

Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis.

Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?

SymBioSys Exercise 2 Cardiac Function Revised and reformatted by C. S. Tritt, Ph.D. Last updated March 20, 2006

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

What is the Role of Surgical Repair in 2012

Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme

The cost-effectiveness of expanded testing for primary HIV infection Coco A

Introduction ABSTRACT

Recording and Evaluation of Co-Morbidity - An Update. Jill Birch University of Manchester

Proton therapy of cancer: potential clinical advantages and cost-effectiveness Lundkvist J, Ekman M, Ericsson S R, Jonsson B, Glimelius B

Economic Model of Multiple Radiation Therapy Treatments for Low-Risk Prostate Cancer: Overview. June 4, Julia Hayes, M.D. Pamela McMahon, Ph.D.

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

How to use the Best Case/Worst Case Communication Tool. Toby C. Campbell MD, MSCI Gretchen Schwarze, MD Amy Zelenski, PhD Sara Johnson, MD

Abdominal Aortic Aneurysm (AAA) General Information. Patient information Leaflet

Section 3: Economic evaluation

Transcription:

Advanced Decision Analysis: Markov Models

Reasons to understand Markov models It s the standard in academia Very powerful/flexible tool simple decision trees relatively inflexible limited time frame hard to model recurring risks Markov models: allow you to model anything (well, almost anything)

Challenges of Markov models More difficult conceptually than simple decision tree models Trickier math rates vs. probabilities

Overview Introduction to Markov models Problems with simple decision trees Markov models general structure how they run rates & probabilities how they keep score (expected value)

Should patients with Bjork-Shiley valves undergo prophylactic replacement? Risks of Outlet Strut Fracture (and its consequences) vs. Risks with reoperation

Clinical Scenario 65 year man with prosthetic valve in 1986 otherwise healthy predicted operative risk 3% 29mm, 70 Björk-Shiley valve strut fracture risk 10.5% at 8 years 63% case-fatality

Four Basic Steps Decision Analysis 1. structure competing strategies and clinical outcomes in a decision model 2. estimate probabilities for clinical outcomes 3. assign values for clinical outcomes (utility) 4. analysis calculate expected values of strategies assess stability of results (sensitivity analysis)

1. Structure model (simple tree) watchful waiting strut fracture die survive/well choose no fracture/well prophylactic reop die survive

2. Assign probabilities choose watchful waiting prophylactic reop strut fracture 0.105 no fracture/well 0.895 die 0.03 survive 0.97 die 0.63 survive/well 0.37

3. Assign values (e.g. in QALYs) choose watchful waiting prophylactic reop strut fracture 0.105 no fracture/well 0.895 die 0.03 survive 0.97 die 0.63 survive/well 0.37 17.9 0 17.9 0 17.9

choose 4(a). Baseline analysis strut fract die 0.63 0 watch wait 0.105 survive 0.37 17.9 no fracture 0.895 17.9 die proph reop 0.03 0 survive 0.97 17.9 U*P 0 0.7 16.0 0 17.4 EV 16.7 QALYS 17.4 QALYS

18.0 4(b). Sensitivity analysis Expected Value (QALYs) 17.6 17.2 16.8 Prophylactic Reoperation Watchful Waiting 16.4 16.0 0 Baseline Threshold 2 4 6 8 Operative Mortality Risk (%) 10

Limitations of simple decision trees Don t account for timing of events Roll the dice once, at time zero Problems with parameter estimates (time) probabilities, dealing with competing risks over time values applied to future outcomes may be underestimated (all bad events considered to be happening immediately)

Problems with simple trees EV 16.7 choose EV 17.4 watchful waiting prophylactic reop strut fracture 0.105 no fracture/well 0.895 die 0.03 survive 0.97 die 0.63 survive/well 0.37 17.9 0 17.9 0 17.9 What if the person lived 20 good years before dying from strut fracture? EV=0???

Markov models to the rescue Definition: iterative model in which hypothetical patients make transitions between health states over time, accumulating QALYs along the way 2 main types: Cohort simulation (large pop of identical patients) Monte Carlo simulation (one pt at a time)

Decision analysis with Markov models Same four basic steps as simple trees structuring the model probabilities assigning values to outcomes baseline and sensitivity analysis But a little more complex

Model structures viewed left to right Simple trees specify alternatives (decision node) chance events (chance nodes) final health states (terminal nodes) Markov models specify alternatives (decision node) parse to health states (intermediate and final) chance events move hypothetical patients between health states

Specifying alternatives watchful waiting choose prophylactic reop

Health states well watchful waiting choose prophylactic reop

Whole model well survive strut fracture watchful waiting well choose well, post-op prophylactic reop 1. Alternatives 2. Health states 3. Cycle trees (end with a health state assignment)

How the model runs Markov cohort simulation hypothetically large cohort start in distribution of health states at time zero some members make transitions between health states with each cycle (Cycle = stage in TreeAge) keep cycling until everyone (or nearly everyone) absorbed into the state

Folding back: Time zero well 1000 pts watchful waiting choose 0 pts 0 pts prophylactic reop 970 pts 30 pts cycle length = 1 year

Folding back: Cycle 1 well 937 pts watchful waiting choose 4 pts 59 pts prophylactic reop 923 pts 77 pts cycle length = 1 year

Folding back: Cycle 10 well 540 pts watchful waiting choose 12pts 448pts prophylactic reop 556 pts 444 pts cycle length = 1 year

Folding back: Cycle 50 well 0 pts watchful waiting choose 0 pts 1000 pts prophylactic reop 0 pts 1000 pts cycle length = 1 year

Decision analysis with Markov models Four components structuring the model (and how it runs) probabilities assigning values to outcomes analysis

Probabilities Events with short time horizons (e.g., op risk) Events that occur over time (e.g., valve-failure) Constant Changing Simple trees Markov models

Events with short time horizons (easy) well survive strut fracture * watchful waiting well choose well, post-op prophylactic reop * 1. Alternatives 2. Health states 3. Cycle trees

Events occurring over time (harder) well * survive * strut fracture choose watchful waiting * well, post-op well prophylactic reop * 1. Alternatives 2. Health states 3. Cycle trees

What you need: Probabilities of events occurring during each cycle of the model (aka transition probabilities)

Problem: Published studies don t give you cycle-specific probabilities

What do you get from literature? Cumulative incidence (e.g., stroke incidence at 5 years was 24% ) Kaplan-Meier plots proportion of population free of event Number of events, size of population

Deriving transition probabilities Data from source studies Step 1 Annual rates Step 2 Cycle-specific probabilities

Step 1. Deriving rates Source Data x-year probability (% pts with event at x years) Rate Formula ln (1 - p) t survival / event-free curve (% pts [f] without event) ln (f) t # events # events/pt-yrs follow-up

Kaplan-meier plot 89.5% free of OSF at 8 years rate = - ln (f) / t Deriving rates: Example = - ln 0.895 / 8 = 0.0139 / yr 100 % free OSF 0 8 = 1.39% / yr Time (yrs) 0 (89.5%)

Deriving transition probabilities Data from source studies Step 1 Rates Step 2 Cycle-specific probabilities

Step 2. Converting rates to transition probabilities Transition probability (p) = 1 e^(-r * t) r = rate, t = cycle length Example: Strut Fx rate = 0.0139; 3 month cycle length p = 1 e^(-0.0139 * 0.25) = 0.00347 TreeAge function: RateToProb

Decision analysis with Markov models Four components structuring the model (and how it runs) probabilities assigning values to outcomes analysis

Simple trees: Assigning values (rewards) one value assigned each terminal node Markov: assigned at each health state can be credited multiple times (with each cycle of the model)

Assigning values to health states ( rewards ) Measures of expected value Costs ($), years of life, QALYs

Accumulating rewards: Cycle 0 to 1 watchful waiting well 1000 pts Cycle 1000 choose 0 pts Cum 1000 0 pts prophylactic reop 970 pts Cycle 970 Incremental reward = cycle length = 1 year 30 pts Cum 970

Accumulating rewards: Cycle 1 to 2 choose watchful waiting well 937 pts 4 pts Cycle 941 Cum 1941 59 pts prophylactic reop 923 pts Cycle 923 Incremental reward = cycle length = 1 year 77 pts Cum 1893

Accumulating reward: Cycle 10 to 11 well 540 pts Cycle 552 choose watchful waiting 12pts Cum 7822 prophylactic reop 448pts 556 pts Cycle 556 444 pts Cum 7810 Incremental reward = cycle length = 1 year

Accumulating reward: Cycle 50 well 0 pts Cycle 0 choose watchful waiting 0 pts Cum 17145 prophylactic reop 1000 pts 0 pts Cycle 0 1000 pts Cum 17411 Incremental reward = cycle length = 1 year

Baseline analysis Strategy Cumulative reward Expected Value Watchful Waiting 17,145 Prophylactic Reoperation 17,411

Baseline analysis Strategy Cumulative reward Expected Value Watchful Waiting 17,145 17.1 years/person Prophylactic Reoperation 17,411 17.4 years/person

How do you incorporate utilities?

Accumulating rewards: Cycle 0 to 1 watchful waiting well 1000 pts Cycle 500 choose 0 pts Cum 500 0 pts prophylactic reop 970 pts Cycle 485 30 pts Incremental reward = 0.5 * 1 year Cum 485

?

Building a Decision Model Your patient is a 65 year old white male with a large abdominal aortic aneurysm. Although asymptomatic, the aneurysm has grown substantially over the last year, from 4.6cm to 6.0cm. You have decided that the aneurysm needs repair. However, the patient also has severe angina and a positive stress test, and cardiac catheterization reveals good ventricular function, but severe coronary disease that is not amenable to PTCA or stenting. Question: Should this patient undergo AAA repair only, AAA repair followed by CABG, or CABG prior to AAA repair?

Basic Steps 1. Structure a decision model 2. Enter probabilities, life expectancy and utility values 3. Perform a baseline analysis 4. Perform sensitivity analysis